Epstein-Barr virus (EBV) infects and efficiently immortalizes human B lymphocytes in cell culture. Similarly, B lymphocytes infected by EBV in vivo are found to be immortalized when cultivated in vitro as are EBV-infected Burkitt lymphoma biopsy cells (see refs. 1 and 2 for reviews). Eleven viral genes are consistently found expressed in B cells immortalized in vitro by EBV and these genes are likely candidates to be required for immortalization. However, only a subset of the 11 genes has been defined by genetic means to be required for this process. EBV nuclear antigen 2 (EBNA2) (3, 4) , latent membrane protein 1 (LMP1) (5), EBNA3a, and EBNA3c (6) were found to be indispensable, whereas other genes can be omitted in the context of the EBV genome. No information has been obtained for EBNA1, which is necessary for viral plasmid replication (7) and presumably for EBV DNA replication in latently EBV-infected cells since the viral genome is usually maintained as plasmid DNA (8) . This function of EBNA1 implies an evident contribution to the process of immortalization. EBNA2 is known to be required to initiate and to maintain immortalization (9) , and it is likely that it acts to upregulate viral and cellular RNA synthesis by interacting with two cellular transcription factors (10) (11) (12) . LMP1, which is also indispensable for B-cell immortalization, scores as an oncogene in established rodent cells (13, 14) ; can alter the state of differentiation of certain human epithelial cell lines (15, 16) ; and is associated with changes in the expression of cell surface differentiation markers under certain conditions (17, 18) . It is likely that LMP1 acts via an unknown signaling pathway at the plasma membrane but its biochemical function remains to be elucidated. The contribution of other EBV genes is even less
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clear. EBNA3a is primarily involved in early events in B-cell immortalization but is not needed for maintenance of B-cell proliferation (19) . Similarly, the function of the EBNA-LP gene appears to be auxiliary but not mandatory for the process of B-cell immortalization in vitro by EBV (3) .
Previously, genetic analysis of EBV genes has relied on recombination events in lymphoblastoid cells between an endogenous EBV genome, usually the defective, nonimmortalizing P3HR1 strain, and a transiently introduced recombinant plasmid, which carries the mutation of interest. The induction of the lytic cycle triggers various homologous and illegitimate recombination events between both DNA molecules. Consequently, the definition of composition of the recombinant progeny viruses is difficult and usually uncertain. Moreover, such a strategy is limited in that only individual genes can be studied genetically and the minimal set of immortalizing genes cannot be defined. To overcome this obstacle, we have taken advantage of mini-EBV plasmids engineered in Escherichia coli that contain defined parts of the EBV genome cloned onto an F plasmid. Here we demonstrate that such a mini-EBV construct when introduced into human primary B lymphocytes of tonsillar origin contains sufficient genetic information to immortalize the transfected B cells. Since these mini-EBV plasmids can be easily manipulated in the prokaryotic host, it will be possible to delineate all the genes of EBV that are both sufficient and necessary for EBV-mediated B-cell immortalization in vitro.
MATERIALS AND METHODS
Construction of the Mini-EBV Plasmid p1495.4. The p1495.4 plasmid was constructed by the chromosomal building technique on the basis of the two cloning vectors pMBO132 and pMBO96 as described (20) . The individual plasmids used for assembling the mini-EBV plasmid p1495.4 are shown in Fig. 1 . In a first step, the plasmid p931.12 was constructed on the basis of the F-plasmid vector pMBO132 and all the remaining plasmids were sequentially added to this first construct in a clockwise fashion. All the other plasmid inserts were established on the basis of pMBO96 or a derivative of it (data not shown). The individual plasmids harbor the following inserts from the B95-8 strain (21) . The combined plasmids were resolved with the aid of the resD expression plasmid pDCM111 via the two rfsF sites present in the cointegrate so that the F-factorbased prokaryotic backbone was retained together with the recombined EBV insert (20) . In consecutive steps, the individual neighboring plasmids were added by homologous recombination and subsequent resolution. All intermediate plasmids and the final constructions were grown in E. coli strain DH5a [F-, F80dlacZAM15, A(lacZYA-argF)U169, deoR, recAl, endAl, hsdRl7 (r,7, mk ), supE44, A-thi-1, gyrA96, relA1] and were carefully checked by restriction enzyme analysis for the desired structures. The assembled construct p1495.4 was calculated to be 83,851 bp.
Preparation and Transfection of Tonsillar B Lymphocytes. Human B lymphocytes were prepared and purified from routine tonsillectomies by generating single cell suspensions and depletion of T lymphocytes by rosetting with sheep red blood cells. The preparations were analyzed by fluorescenceactivated cell sorter and were found to be >95% positive for the panB marker CD19. Ten micrograms of p1495.4 plasmid DNA was introduced into 1 X 107 tonsillar human B-lymphocyte preparations in a vol of 250,l by electroporation (23) with a Bio-Rad electroporator at 320 V or at 340 V, 960 ,F, in a 0.4-cm-wide cuvette. The electroporated cells were initially plated in 96-well cluster plates at a density of -5 X 104 cells per well on irradiated (5000 rad; 1 rad = 0.01 Gy) human fibroblast feeder layers (WI38 or MRC5 human fibroblast cells obtained from the American Type Culture Collection) in RPMI 1640 culture medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1 mM pyruvate, 100 units of penicillin per ml, and 100 gg of streptomycin per ml. The clones that proliferated were expanded and total cell DNA was isolated from -1 x 107 cells as described (19) .
Analysis of Immortalized B-Cell Clones. The p1495.4-related DNA was detected by Southern blot hybridization (24) with either pMBO132 plasmid DNA, which visualizes the plasmid backbone of p1495.4 ( Fig. 2b) , or with the cosmid probe cMB-14 (27) , which spans DNA from nucleotides 48,040-87,237 of the B95-8 strain of EBV ( Fig. 2 c and d ).
Other probes used to verify the predicted structure of p1495.4 and the absence of any wild-type EBV DNA included a mixture of different cloned EBV fragments (27) (Fig. 2a) . For PCR analysis, the primer sets used have been described (19 Fig. 2c. probe to detect individual immunoglobulin rearrangements (Fig. 3) .
RESULTS
Construction of the p1495.4 Mini-EBV Plasmid. The contributions of EBV to the process of B-cell immortalization (1, 2) have been especially difficult to study because the size of the viral genome [172 kbp in the B95-8 prototype strain (21) ] prevents its manipulation by common recombinant DNA procedures. All current procedures are limited and rely on packaging of subgenomic plasmids into an EBV virion coat (3) or fortuitous homologous recombination events (4) (5) (6) (30) (31) (32) (33) (34) . We have circumvented this problem by constructing a plasmid in E. coli that contains 71 kbp of EBV DNA cloned onto an F plasmid. This was achieved by a multistep chromosomal building technique that relies on an initial F-factor plasmid, which is used to add fragments of DNA by a combination of homologous and site-specific recombinations in E. coli. This approach allows the defined composition of the DNA and also permits the final plasmid to be altered or enlarged at any predetermined position (20) . To assemble the recombinant DNA used in this study eight plasmids derived from the immortalizing B95-8 strain of EBV were sequentially joined into a mini-EBV plasmid (Fig. 1) that contains all the known genetic loci involved in B-cell immortalization. The mini-EBV plasmid termed p1495.4 also encompasses the EBV plasmid origin of DNA replication, oriP, which together with the viral gene product EBNA1 (Fig. 1) allows the extrachromosomal maintenance of the mini-EBV plasmids (7, 22, 35) . Having established such a mini-EBV plasmid with the total size of 83,851 bp including the prokaryotic plasmid backbone, we tested its functionality by DNA transfection into human primary B lymphocytes. We prepared tonsillar B cells and transfected the cells by electroporation with the p1495.4 mini-EBV DNA. Analysis of B-Cell Clones Immortalized by p1495.4. In several independent experiments with tonsillar B lymphocytes, different numbers of single-cell clones grew out from cells that had been transfected with p1495.4 DNA, whereas only one clone was established from cells electroporated with the control plasmid pCMV-LTR-Luc (Table 1) . To monitor transfection efficiencies we used this very potent reporter plasmid in which the luciferase gene is expressed under the control of an artificial cytomegalovirus/human immunodeficiency virus long terminal repeat promoter. Under the conditions of electroporation used in this study, we were unable in most experiments to achieve detectable expression of the luciferase gene product in a highly sensitive luminometer assay (data not shown). This finding is in agreement with the notion that primary B lymphocytes are peculiarly recalcitrant to the uptake and expression of foreign DNA.
Thirty-nine of 48 clones that had been transfected with p1495.4 DNA were analyzed by Southern blotting and all but one were found to carry p1495.4 mini-EBV DNA and no wild-type EBV (Fig. 2) . As expected, no trace of wild-type EBV DNA could be found in 38 B-cell clones transfected with p1495.4 DNA (Fig. 2a) , which could be confirmed by very sensitive PCR analyses which easily detect less than five copies of wild-type EBV DNA in 20,000 genome equivalents (data not shown) (19) . One of the clones analyzed was infected with a wild-type EBV strain derived from the patient's tonsils (clone 5 in Figs. 2 and 3) , which presumably also gave rise to the single B-cell clone in the negative control ( Table 1 ). The composition of the p1495.4 DNA was carefully checked by Southern blot hybridizations in the majority of proliferating clones and the mini-EBV DNA was found to be intact and unaltered in most of the clones analyzed (Fig. 2 b and c; data not shown). Long-term in vitro cultivation (>12 months) of the B-cell clones indicated that they are immortalized. Immunoglobulin heavy-chain rearrangements in the cell lines were analyzed by Southern blot hybridization, which confirmed the individual nature of the immortalized B-cell clones (Fig. 3) . As expected, the transfected mini-EBV DNA was maintained as extrachromosomal plasmids as determined by the Gardella gel technique (37, 38) and all the cell clones were B lymphocytes as judged by fluorescence-activated cell sorter analysis with antibodies against differentiation antigens CD19 and CD3 (data not shown).
DISCUSSION
The mini-EBV p1495.4 contains -40% of the DNA of EBV and is sufficient to immortalize human B lymphocytes in vitro. Attempts to activate the lymphocytes by different means prior to DNA transfection were unsuccessful (data not shown), which might indicate that no contribution from the virus particle apart from its DNA is required for immortalization.
The recombinant mini-EBV vector is of particular interest for applications including expression of introduced foreign genes in virus-free human B lymphocytes. Because cells can be easily established from any human donor with this mini-EBV, it can also be used for human gene therapy. It is especially fortunate that the chromosomal building technique in E. coli has no real practical limitations (20) ; the mini-EBVs can readily accommodate several more genes of interest. It is also clear that the composition of a given mini-EBV can be altered at any desired position (20) so that individual EBV genes involved in the control of proliferation of human B lymphocytes can be dissected genetically. We have already established that much smaller mini-EBVs will support the immortalization of human B lymphocytes (unpublished data); therefore, we should be able define the minimal set of viral genes necessary to immortalize human primary B lymphocytes in vitro.
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